

## TORRENT PHARMACEUTICALS LIMITED

Registered Office: Torrent House, Off Ashram Road, Ahmedabad - 380 009, Ph.: + 91 79 26599000 Fax: + 91 79 26582100 CIN: L24230GJ1972PLC002126; Website:www.torrentpharma.com; Email: investorservices@torrentpharma.com

(Rs. in crores except per share data) Statement of Consolidated Financial Results for the Quarter and Year ended 31-Mar-2023 Quarter ended Year ended 31-Dec-2022 31-Mar-2023 31-Mar-2022 **Particulars** Unaudited 31-Mar-2023 31-Mar-2022 **Audited Audited** (Restated, **Audited Audited** (Refer note 6) (Refer note 6) Refer note 8) Income 2452 2459 2104 Net sales 9464 8419 Other operating income 39 32 27 156 89 2491 Revenue from operations (net) 2491 2131 9620 8508 Other income (10)45 56 197 **Total income** 2500 2481 2187 9665 8705 **Expenses** Cost of materials consumed 388 350 397 1480 1538 Purchases of stock-in-trade 268 350 234 1089 831 Changes in inventories of finished goods, work-in-progress and stock-in-trade 48 30 (9)166 74 441 423 364 1678 Employee benefits expense 1526 Finance costs 107 102 57 333 255 Depreciation amortisation and impairment expense 196 193 162 707 662 619 614 584 2365 2108 Other expenses 2067 2062 1789 **Total expenses** 7818 6994 Profit before exceptional items and tax 433 419 398 1847 1711 Exceptional items (Refer Note 9) 485 485 Profit before tax 433 419 (87)1847 1226 Tax expense Current tax 100 70 85 355 346 Deferred tax charge/ (credit) (Refer Note 7) 29 55 (51)228 107 Short provision of earlier periods 17 (3)19 (4)146 602 Total tax expense 127 31 449 Net profit for the period 287 292 (118)1245 777 Attributable to: Owners of the company 287 292 (118)1245 777 - Non controlling Interest Other comprehensive income Items that will not be reclassified subsequently to profit or 28 (7)20 9 9 Income tax relating to items that will not be reclassified subsequently to profit or loss (11)2 (3)(5)1 Items that will be reclassified subsequently to profit or loss 35 (45)(10)(179)3 Income tax relating to items that will be reclassified subsequently to profit or loss (9) 38 (1) Total other comprehensive income 43 (41)11 (137)12 **Total comprehensive Income** 330 251 (107)1108 789 Attributable to: 330 251 (107)1108 789 - Owners of the company - Non controlling Interest 169.23 169.23 169.23 84.62 Paid-up equity share capital (Face value of Rs. 5 each) 84.62 6029 5868 Other equity excluding revaluation reserves Earnings per share (of Rs. 5/- each) (not annualised for the quarter): (Refer Note 11) 36.79 22.96 Basic 8.48 8.63 (3.49)(3.49)36.79 Diluted 8.48 8.63 22.96



## Notes:

- The above results were reviewed by the Audit Committee and approved by the Board of Directors of the Parent Company, in their respective meetings held on 30-May-2023. The auditors have carried out audit of the above said results. There is no qualification in the auditors' report on this statement of financial results.
- 2 The consolidated financial results include the financial results of sixteen wholly owned subsidiaries.
- 3 The Group operates in a single segment i.e Generic Formulation Business.
- 4 Consolidated Balance Sheet

(Rs. in crores)

	Audited			
Particulars	As at	As at		
	31-Mar-2023	31-Mar-2022		
ASSETS				
Non-current assets	**	,		
Property, plant and equipment	2627	2575		
Capital work-in-progress	688	544		
Right-of-use assets	145	128		
Goodwill	338	259		
Other intangible assets	5012	3461		
Intangible assets under development	77	85		
Financial assets		i.		
Investments	43	42		
Loans	2	2		
Other financial assets	49	67		
	94	111		
Income tax assets (net)	136	122		
Deferred tax assets (net)	544	494		
Other non-current assets	22	26		
Sub-total - Non-current assets	9683	7805		
Current assets				
Inventories	2230	2462		
Financial assets				
Investments	156	184		
Trade receivables	1944	1633		
Cash and cash equivalents	508	398		
Bank balances other than cash and cash	63	5		
equivalents				
Loans	2	3		
Other financial assets	108	168		
A	2781	2391		
Other current assets	303	312		
Sub-total - Current assets	5314	5165		
Non-current assets held for sale	15	130		
TOTAL - ASSETS	15012	13100		



100			
IRS.	ın	crores)	

	(Rs. in crores)			
	Auc	lited		
Particulars	As at	As at		
	31-Mar-2023	31-Mar-2022		
EQUITY AND LIABILITIES				
Equity		8		
Equity share capital	169	85		
Other Equity	6029	5868		
Sub-total - Equity	6198	5953		
Non-current liabilities				
Financial liabilities				
Borrowings	2496	2123		
Lease Liabilities	53	37		
Other financial liabilities	21	5		
	2570	2165		
Provisions	393	369		
Deferred tax liabilities (net)	402	194		
Other non-current liabilities	2	4		
Sub-total - Non-current liabilities	3367	2732.		
Current liabilities				
Financial liabilities				
Borrowings	2801	1895		
Lease Liabilities	18	15		
Trade payables				
Total outstanding dues of micro	18	20		
enterprises and small enterprises				
Total outstanding dues of creditors other	1661	1654		
than micro enterprises and small	4.			
enterprises				
Other financial liabilities	421	279		
	4919	3863		
Provisions	394	411		
Current tax liabilities (net)	31	42		
Other current liabilities	103	99		
Sub-total - Current liabilities	5447	4415		
TOTAL - EQUITY AND LIABILITIES	15012	13100		

## **Consolidated Statement of Cash Flows**

5

(Rs. in crores)

	Audited		
Particulars	Year ended 31-Mar-2023	Year ended 31-Mar-2022	
CASH FLOWS FROM OPERATING ACTIVITIES	,		
PROFIT BEFORE TAX	1847	1226	
Adjustments for :			
Depreciation, amortization and impairment expense	707	662	
Allowance for expected credit loss (net)	2	1	
Exceptional items (Refer Note 9(ii))	-	485	
Unrealised foreign exchange gain (net)	(49)	(36)	
(Profit)/Loss on sale / discard / write-off of property, plant & equipments	(22)	1	
Net gain on sale of investments	(19)	(10)	
Finance costs	333	255	
Interest income	(15)	(7)	
	2784	2577	
Adjustments for changes in working capital:	, 1		
Trade receivables	(290)	(109)	
Loans and other assets	(19)	(4)	
Inventories	256	219	
Trade payables	(58)	(393)	
Liabilities and provisions	93	(66)	
CASH GENERATED FROM OPERATIONS	2766	2224	
Income taxes paid (net of refunds)	(398)	(421)	
NET CASH FROM OPERATING ACTIVITIES	2368	1803	



	Audited			
articulars Year 31-Ma		Year ended 31-Mar-2022		
CASH FLOWS FROM INVESTING ACTIVITIES				
Purchase of property, plant and equipments and	(574)	(203)		
intangible assets (including payment towards capital				
work-in-progress and capital advances paid)				
Proceeds from sale of property, plant and equipment	159	6		
and intangible assets (including assets held for sale)				
Acquisition of subsidiaries (Refer Note 8)	(2000)			
Redemptions of / (Investments in) mutual funds (net)	47	(35)		
Fixed deposits matured (net)	(60)	27		
Interest received	13	7		
NET CASH USED IN INVESTING ACTIVITIES	(2415)	(198)		
CASH FLOWS FROM FINANCING ACTIVITIES				
Proceeds from long-term borrowings	1395	-		
Repayment of long-term borrowings	(972)	(1033)		
Proceeds from short term borrowings (net)	842	219		
Repayment of lease obligations	(22)	(32)		
Dividend paid	(863)	(677)		
Finance costs paid	(303)	(258)		
NET CASH FROM / (USED IN) FINANCING ACTIVITIES	77	(1781)		
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS	30	(176)		
Effect of exchange rate changes on foreign currency cash and cash equivalents	21	1		
Amount transferred consequent to Amalgamation (Refer Note 8)	59	-		
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF YEAR	398	573		
CASH AND CASH EQUIVALENTS AT THE END OF YEAR	508	398		

- Figures for the quarter ended 31-Mar-2023 and 31-Mar-2022 represents the difference between the audited figures in respect to the full financial year and the published figures of nine months ended 31-Dec-2022 (as restated as per note 8 below) and 31-Dec-2021, respectively, which were subjected to limited review.
- Deferred tax expense for the year ended 31-Mar-2023 includes Rs. 197 crores (Previous year : Rs. 242 Crores) on account of MAT credit utilisation.
- The Parent Company has acquired 100% shares of Curatio Healthcare (I) Private Limited ("Curatio") including its two subsidiaries, on 14-Oct-2022, for a total consideration of Rs. 2,000 crores. The Board of Directors of the Company, at its meeting held on 21-Dec-2022, had approved the Scheme of Arrangement in the nature of Amalgamation ('Scheme') of Curatio with the Parent Company subject to requisite statutory and regulatory approvals. The Scheme was filed and approved by the National Company Law Tribunal ('NCLT'), Ahmedabad Bench on 17-May-2023. The parent Company has accounted for the transaction in accordance with Ind AS 103, "Business Combinations", and fair value of identifiable assets acquired and liabilities assumed as at appointed date pertaining to Curatio has been recognised in the consolidated financial statements of the Group based on purchase price allocation as determined by independent valuer. The figures for quarter ended 31-Dec-2022 has been restated to give effect of amalgamation.
- (i) Pursuant to acquisition of acquiree, the Group had recognised deferred tax liability of Rs. 459 Crores, being the difference between book base and tax base with a corresponding effect as part of Goodwill. As a result of amalgamation referred to in note 8 above and consequent alignment between book base and its tax base, the deferred tax liability and the corresponding goodwill was reversed during the quarter.
  - (ii) Exceptional items for the quarter and year ended 31-Mar-2022 relates to discontinuation of the liquid facility in the US based on assessment of its financial viability and considering incremental investments required for bringing the pipeline products into the market and increased competition intensity.
- 10 The Board of Directors in their meeting held on 30-May-2023, recommended a final equity dividend of Rs. 🞖 /- per equity share.



Pursuant to approval given by its shareholders, the parent company has during the year ended 31-Mar-2023, issued 16,92,22,720 equity 11 shares of Rs. 5/- each as fully paid-up bonus equity shares in the ratio of 1 (one) equity share for every 1 (one) existing equity share. Accordingly, the earnings per share has been adjusted for previous periods / year and presented in accordance with Ind AS 33 , Earnings Per

Refer Annexure I for disclosure required pursuant to Regulation 52(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 12 2015 (as amended).

FOR TORRENT PHARMACEUTICALS LIMITED

cutive Chairman

DIN: 00061903

Place: Mumbai, Maharashtra

Date: 30-May-2023

Additional Disclosure as per regulation 52(4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

	y				WHATE SHEET AND ADDRESS OF THE PARTY OF THE	3
Particulars	Regulation No.	Quarter ended			Year ended	
		31-Mar-2023	31-Dec-2022	31-Mar-2022	31-Mar-2023	31-Mar-2022
			(Restated)			
Paid up debt capital		1273	1273	1241	1273	1241
Networth	52(4)(f)	6198	6342	5953	6198	5953
Debenture redemption reserve	52(4)(e)	107	107	143	107	143
Debt equity ratio (in times)	52(4)(a)	0.85	0.86	0.67	0.85	0.67
Debt service coverage ratio (in times)	52(4)(b)	2.43	1.65	2.19	1.89	1.73
Interest service coverage ratio (in times)	52(4)(c)	5.76	6.33	9.88	7.55	9.02
Current ratio (in times)	52(4)(i)	0.98	1.00	1.20	0.98	1.20
Long term debt to working capital (in times)	52(4)(j)	3.85	3.45	1.67	3.85	1.67
Bad debts to Account receivables ratio (in times)	52(4)(k)	0.01	0.00	0.00	0.01	0.00
Current liability ratio (in times)	52(4)(1)	0.62	0.58	0.62	0.62	0.62
Total debts to total assets (in times)	52(4)(m)	0.35	0.34	0.31	0.35	0.31
Debtors turnover (in times) (Annualised)	52(4)(n)	4.96	5.23	5.33	5.29	5.34
Inventory turnover (in times) (Annualised)	52(4)(o)	4.32	4.24	3.36	4.03	3.27
Operating margin (in %)	52(4)(p)	29.1%	28.6%	28.7%	29.9%	30.8%
Net profit margin (in %)	52(4)(q)	11.5%	11.7%	-5.5%	12.9%	9.1%

Ratios have been computed as follows :-

(a) Debt equity ratio: Total debt / Net worth

Total debt: Long term borrowings (incl. current maturities of long term borrowings) + Short tem borrowings

Net worth: Equity share capital + Other equity

- (b) Debt service coverage ratio: (Profit after tax + Deferred tax + Depreciation and amortisation + Interest on debt and lease + Exceptional items) / (Interest on debt and lease + Principal repayments of long term debt including lease payment)
- (c) Interest service coverage ratio: (Profit after tax + Deferred tax + Depreciation and amortisation + Interest on debt and lease + Exceptional items) / Interest on debt and lease
- (d) Current Ratio: Current assets / Current liabilities
- (e) Long term debt to working capital: Long term debt (incl. current maturities of borrowings) / Net working capital Net Working capital: current assets - current liabilities (excl. current maturities of long term borrowings)
- (f) Bad debts to Account receivables ratio: Allowances for credit loss / Gross trade receivables
- (g) Current liability ratio: Current liabilities / Total liabilities (excl. total equity)
- (h) Total debts to total assets: Total borrowing / Total assets

Total borrowing: long term borrowings + current maturities of long term borrowings + short term borrowings

- (i) Debtors turnover: Net sales / Average trade receivables
- (j) Inventory turnover : Net sales / Average Inventories
- (k) Operating margin %: Revenue from operations (net) (cost of goods sold + employee benefits + other expenses) + (other income interest income Dividend income) / Revenue from operations (net)
- (I) Net profit margin %: Profit after tax / Revenue from operations (net)

